Physician profile
Scott Marsteller
NPI 1891714937
$3,766.58
in general payments reported to CMS, 2019-2025
36 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $102 · 2021: $454 · 2022: $318 · 2023: $760 · 2024: $899 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,892.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.14 | 2021-2025 | |
| Novo Nordisk INC | $502.07 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $308.27 | 2021-2025 | Farxiga, Bevespi Aerosphere |
| Pfizer INC. | $274.20 | 2021-2025 | |
| Lilly USA, LLC | $208.08 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $202.98 | 2023-2025 | Repatha, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $188.71 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $170.55 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $132.54 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $131.82 | 2021-2025 | Trintellix |
| Abbott Laboratories | $106.71 | 2021-2025 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $101.37 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.65 | 2021-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $74.30 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $65.50 | 2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Marsteller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.